serna bio

We move into 2026 with the same commitment: 𝘤𝘰𝘮𝘮𝘦𝘳𝘤𝘪𝘢𝘭𝘪𝘻𝘪𝘯𝘨 𝘪𝘯𝘯𝘰𝘷𝘢𝘵𝘪𝘷𝘦 𝘵𝘩𝘦𝘳𝘢𝘱𝘦𝘶𝘵𝘪𝘤𝘴 𝘧𝘰𝘳 𝘳𝘢𝘳𝘦 𝘥𝘪𝘴𝘦𝘢𝘴𝘦𝘴, proudly supported by our SAB, like Jeff Ajer, expert in delivering transformative therapies, critical to our progress.

Join us as we celebrate our 2025 achievements! This year's wins bring us one step closer to our goal of unlocking the transcriptome to treat diseases of high-unmet medical needs. We’re now ready for 2026!
#rna #AIDrugDiscovery #biotech

In a new article by Shekhar Jadhav et al. - "the scientists observed the assembly of a self-splicing ribozyme – an RNA molecule that can ‘cut and paste’ its own sequence, essentially editing itself to become operational. " -
nature.com/articles/s4146…

🎉 We are very excited to announce that we have been selected by the @TargetALS_fdn to be part of the 2025 Drug Discovery Consortia program!
This will further our collaborative efforts with the Universities of Michigan and Dundee to develop a Splicing Modulator for #ALS.

*𝗔𝗻𝗻𝗼𝘂𝗻𝗰𝗲𝗺𝗲𝗻𝘁*
With an incredible set of wins this year, we are planning for #JPM2026. If you're at JPM and want to meet our CEO 𝗥𝗮𝗯𝗶𝗮 𝗧. 𝗞𝗵𝗮𝗻, get in touch!
#JPM2026 #startup #RNA